Abryl Laboratories Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 36.31 Cr
as on 17-07-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.33 M
as on 17-07-2024
- Revenue -74.80%
(FY 2023)
- Profit 83.60%
(FY 2023)
- Ebitda 12.86%
(FY 2023)
- Net Worth -0.59%
(FY 2023)
- Total Assets 13.77%
(FY 2023)
About Abryl Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 40.00 Cr and a paid-up capital of Rs 36.31 Cr.
The company has closed loans amounting to ₹3.33 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Abryl Laboratories Private Limited India is Arshpreet Guliani as COMPANY SECRETARY. Vijay Kumar and Jayant Singla serve as directors at the Company.
- CIN/LLPIN
U24232CH2016PTC035904
- Company No.
035904
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jan 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Abryl Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Arshpreet Guliani | Company Secretary | 15-Apr-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Kumar  | Director | 20-Jan-2016 | Current |
| Jayant Singla | Director | 20-Jan-2016 | Current |
Financial Performance of Abryl Laboratories.
Abryl Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 74.8% decrease. The company also saw a substantial improvement in profitability, with a 83.6% increase in profit. The company's net worth dipped by a decrease of 0.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abryl Laboratories?
In 2023, Abryl Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Aug 2019 | ₹1.66 M | Satisfied |
Hdfc Bank Limited Creation Date: 19 Aug 2019 | ₹1.66 M | Satisfied |
How Many Employees Work at Abryl Laboratories?
Abryl Laboratories has a workforce of 449 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abryl Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abryl Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
